{"id":"bilastin","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":null,"aliases":["Bilaxten"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Histamine H1 receptor"},"_scrapedAt":"2026-03-28T01:04:22.064Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:42:11.966994+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Allergic rhinitis","diseaseId":"allergic-rhinitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Urticaria","diseaseId":"urticaria","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02213367","phase":"PHASE3","title":"Bilastine Updosing in Chronic Spontaneous Urticaria","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2014-07","conditions":"Chronic Urticaria","enrollment":30}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"AGITATION"},{"count":2,"reaction":"ANXIETY"},{"count":2,"reaction":"ASPARTATE AMINOTRANSFERASE INCREASED"},{"count":2,"reaction":"FATIGUE"},{"count":2,"reaction":"HYPOAESTHESIA"},{"count":2,"reaction":"PYREXIA"},{"count":1,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"},{"count":1,"reaction":"ANAEMIA"},{"count":1,"reaction":"APHONIA"},{"count":1,"reaction":"ARRHYTHMIA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":1,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_3","status":"active","brandName":"Bilastin","genericName":"Bilastin","companyName":"Charite University, Berlin, Germany","companyId":"charite-university-berlin-germany","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bilastin is a small molecule that acts as an inverse agonist of the histamine H1 receptor. It is used to treat chronic urticaria, specifically in a condition known as chronic spontaneous urticaria.","enrichmentLevel":5,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:42:11.966994+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}